close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

136.06 -1.90 (-1.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher ↗
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before. 
Via Investor's Business Daily
News headline image
3 Stocks at the Forefront of Medical Innovation ↗
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. 
Via InvestorPlace
News headline image
NASDAQ:NBIX—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. ↗
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in December ↗
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
News headline image
Analyst Expectations for Neurocrine Biosciences's Future ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days ↗
Cassava Sciences sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
News headline image
Are These Biotechs Ready To Launch? ↗
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
News headline image
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise ↗
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX. ↗
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
News headline image
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News ↗
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
Earnings Outlook For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating ↗
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
News headline image
Why Is Neurocrine Biosciences Stock Trading Lower Today? ↗
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)  
Via Benzinga
News headline image
3 Biotech Moonshots to Bet on the Future of Health ↗
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
News headline image
Raymond James Maintains Outperform Rating for Neurocrine Biosciences: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
What 22 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
Despite its growth, NASDAQ:NBIX remains within the realm of affordability. ↗
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Why Is Neurocrine Biosciences Shares Trading Higher Today? ↗
Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH)... 
Via Benzinga
News headline image
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today